The Claim
Pegvisomant, a growth hormone antagonist, inhibits MEK/ERK activation and PPARγ Ser273 phosphorylation in human adipocytes, demonstrating that growth hormone signaling through its receptor directly initiates this lipolytic pathway.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Pegvisomant prevents specific molecular signals in human fat cells that are triggered by growth hormone, confirming that growth hormone acts directly on these cells to activate fat breakdown pathways.
See the scientific wording
Growth hormone antagonist pegvisomant blocks MEK/ERK activation and PPARγ Ser273 phosphorylation in human adipocytes, confirming that GH acts directly through its receptor to initiate this lipolytic pathway.
Growth hormone binds to its receptor on fat cells, turning on a chain reaction that activates MEK and ERK proteins. These proteins then modify a key fat-regulating molecule called PPARγ by adding a phosphate group at a specific spot, causing it to leave the nucleus. Without PPARγ in the nucleus, a protein that blocks fat breakdown is turned off, allowing fat to be broken down and released.
What the research says
1 studyStudy: Growth hormone acts along the PPARγ-FSP27 axis to stimulate lipolysis in human adipocytes.
When scientists blocked growth hormone in human fat cells, they saw that a key chain reaction causing fat breakdown stopped—proving that growth hormone is what starts this process in the first place.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.